Donanemab for Alzheimer's Disease
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Age
- 55 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 550 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
This trial is looking for people who have previously participated in a related study and who want to see if they benefit from yearly doses of donanemab. Participants will attend up to 6 visits during the study, which lasts up to 2.5 years.
You may be able to join if
- I have completed study AACM Addendum 7.
- I have a reliable study partner who knows my daily activities.
- I am assigned female at birth and not able to become pregnant, or I am assigned male at birth.
You may not be able to join if
- I have a serious illness that may affect my participation.
- I have claustrophobia or incompatible metal implants that prevent an MRI.
- I have any brain condition or injury that may be unsafe.
- I cannot have PET scans due to medical reasons.
- I have received amyloid-targeting therapy other than donanemab.
- I have participated in another clinical trial in the last 30 days.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Loading trial locations…
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
CONTACT
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
CONTACT